Shutting off the fuel supply to target metabolic vulnerabilities in multiple myeloma

• Published in: Frontiers in oncology Vol. 13; p. 1141851
• Main Authors: Rana, Priyanka S, Goparaju, Krishna, Driscoll, James J
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 08.06.2023
• Subjects: fatty acid synthesis; glycolysis; metabolism; multiple myeloma; Oncology; oxidative phosphorylation; proteasome inhibitor; multiple myeloma; metabolism; proteasome inhibitor; fatty acid synthesis; oxidative phosphorylation; glycolysis
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2023.1141851

Pathways that govern cellular bioenergetics are deregulated in tumor cells and represent a hallmark of cancer. Tumor cells have the capacity to reprogram pathways that control nutrient acquisition, anabolism and catabolism to enhance their growth and survival. Tumorigenesis requires the autonomous reprogramming of key metabolic pathways that obtain, generate and produce metabolites from a nutrient-deprived tumor microenvironment to meet the increased bioenergetic demands of cancer cells. Intra- and extracellular factors also have a profound effect on gene expression to drive metabolic pathway reprogramming in not only cancer cells but also surrounding cell types that contribute to anti-tumor immunity. Despite a vast amount of genetic and histologic heterogeneity within and between cancer types, a finite set of pathways are commonly deregulated to support anabolism, catabolism and redox balance. Multiple myeloma (MM) is the second most common hematologic malignancy in adults and remains incurable in the vast majority of patients. Genetic events and the hypoxic bone marrow milieu deregulate glycolysis, glutaminolysis and fatty acid synthesis in MM cells to promote their proliferation, survival, metastasis, drug resistance and evasion of immunosurveillance. Here, we discuss mechanisms that disrupt metabolic pathways in MM cells to support the development of therapeutic resistance and thwart the effects of anti-myeloma immunity. A better understanding of the events that reprogram metabolism in myeloma and immune cells may reveal unforeseen vulnerabilities and advance the rational design of drug cocktails that improve patient survival.